The American Cannabis Market is a Major Growth Opportunity for Creso Pharma and its Planned Deal With CERES Natural Remedies Will Help the Company Establish a U.S. Presence Ahead of Likely Federal Legalization
CERES’ Operating Business, High Fidelity is Vermont’s Largest Independent Cannabis Company and Through its Established Footprint, Has Generated Over USD $35 Million in Revenue Since 2013
Creso Pharma (ASX: CPH) (OTC: COPHF) (FRA: 1X8) announced that it has executed a non-binding letter of intent (LOI) with leading CBD and plant-based remedies provider CERES Natural Remedies to distribute and sell Creso’s range of CBD and hemp animal health products anibidiol, in the USA.
CERES is a leading Vermont headquartered distribution company, specializing in plant-based remedies and CBD and hemp products for the U.S. market. It is the sister company to Champlain Valley Dispensary, Vermont’s first licensed and only independent medicinal cannabis company.
Champlain Valley Dispensary and CERES are both subsidiaries of High Fidelity, Vermont’s largest independent cannabis company. High Fidelity currently operates two of the five vertically integrated cannabis licences available in the state and services 70% of registered patients. Since 2013, High Fidelity has generated in excess of US$35 million in revenue.
CERES has three traditional retail stores in Vermont and access to over 50,000 distribution outlets across the country. It services a number of high-growth customer segments, including conventional and convenience-based grocery stores, colleges and universities, fast food outlets, natural grocers and medicinal and recreational cannabis dispensaries. In addition to its own branded products, CERES has a strong track record of scaling up regional, national and international brands through its sales channels. Creso expects to leverage CERES’ established relationships to expand the Company’s footprint into the U.S.
Under the agreement, the parties have agreed to enter into a formal commercial agreement on or before 1 April 2021 setting out the terms upon which CERES will sell Creso’s anibidiol animal health products through its established distribution network in the US, subject to federal legalization of CBD in the U.S.
Initially, it is intended that CERES will focus on Vermont, Maine, New Hampshire, New York, Connecticut, Massachusetts and Rhode Island and explore opportunities to target additional states across the U.S.
Creso and Ceres will work together collectively to prepare to sell and distribute within the US market upon legislation occurring which both groups believe will happen in 2021.
The initial term of the agreement is one year and will automatically renew after one year unless either party notifies the other of their decision to not renew the agreement within 90 days prior to the expiry of the initial or renewal term. Initial Term and renewal terms are subject to termination for cause upon notice by either party or upon failure to meet the above-referenced renewal conditions.
CERES will aim to achieve a target of at least US$5 million in sales over a two-year period, subject to federal legalization of CBD in the US. The Company has recently witnessed a considerable shift in the regulation of cannabis globally and eagerly awaits legislative reform in the U.S. Creso and Ceres are forming the view this legislation may occur at some point during 2021 and intend to formalize the commercial agreement quickly in order to be able to move swiftly upon such legislation occurring.
The US represents a large, emerging addressable market for Creso. The global CBD pet supplements market was valued at US$27.7m in 2019 and is anticipated to grow at a 40% compound average growth rate from 2020 to 20271. This agreement leaves Creso very well placed to benefit with sales expected to materially add to the Company’s growing revenue profile.
“Entering the US market with a high calibre partner such as CERES is a major achievement for Creso Pharma and we look forward to working with the group to outline a progress of the launch of anibidiol® across the country. Importantly, CERES has an established distribution footprint and relationships with over 50,000 stores across the country, as well as a track record of scaling up its own branded products and international offerings. To this end, we are very confident that our animal health products will be well received,” commented Adam Blumenthal, Creso Pharma’s non-executive Chairman.
“We are excited to partner with Creso Pharma to introduce the Company’s industry-leading animal healthcare products to the US market. We continue to witness rapid demand for CBD and hemp-based pet health products through our network and anticipate anibidiol® to be very well received.” “We look forward to working with Creso’s management team to explore additional growth opportunities which will benefit both parties and create a long-term, value accretive partnership,” stated CERES Executive Director, Shayne Lynn.
“We will continue to monitor regulatory and policy shifts in the US to ensure the Company and CERES are primed for launch and expect first sales to add to the Company’s revenue streams. Creso has a number of exciting growth initiatives across all key operating business pending and we look forward to updating shareholders as they materialise in the coming months,” added Blumenthal.
Per Investopedia: “In technical analysis, a pennant is a type of continuation pattern formed when there is a large movement in a security, known as the flagpole, followed by a consolidation period with converging trend lines—the pennant—followed by a breakout movement in the same direction as the initial large movement, which represents the second half of the flagpole.”
This U.S. Cannabis Stock Appears to Be Way Undervalued and May Actually Benefit From a Second Wave of the Pandemic
Creso Pharma is a paid client of The Cannabis Investor. The Cannabis Investor does not hold a position in CPH.
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.